A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
Public ClinicalTrials.gov record NCT01989325. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. Approximately 75 patients from the US will be enrolled in this study.
Study identification
- NCT ID
- NCT01989325
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 77 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2013
- Primary completion
- Jan 31, 2016
- Completion
- Apr 30, 2016
- Last update posted
- Sep 15, 2020
2013 – 2016
United States locations
- U.S. sites
- 22
- U.S. states
- 19
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| UCLA | Los Angeles | California | 90095 | — |
| St. Joseph Heritage Healthcare | Santa Rosa | California | 95403 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33905 | — |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | Illinois | 60611 | — |
| Crescent City Research Consortium | Marrero | Louisiana | 70072 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Forrest General Cancer Center | Hattiesburg | Mississippi | 39401 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Memorial Sloan Kettering | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Oncology Hematology Care - Blue Ash | Cincinnati | Ohio | 45242 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Knight Cancer Institute at Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Prairie Lakes Health Care System | Watertown | South Dakota | 57201 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Simmons Cancer Center - UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| WVU - Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506 | — |
| Medical College of Wisconsin Cancer Center | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01989325, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2020 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01989325 live on ClinicalTrials.gov.